Kidney Disease
163
129-144 of 148
- SGLT2 inhibition in CKD: Discussing the key questions & evidenceThe clinical landscape of managing patients with CKD
Prof. David Cherney
- CDMC 2018: Shifting gears in the management of diabetes and CVDTranslating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
Dr. Adie Viljoen, MD
- CDMC 2018: Shifting gears in the management of diabetes and CVDBenefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
Prof. Eduard Montanya, MD
Steve Wiviott, MD
- Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibitionRemaining questions on SGLT2 inhibition & CKD: A review of new outcome trials
Prof. Colin Baigent
- Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibitionSGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME
Prof. Christoph Wanner
- Epigenetics in CKD & CVD: A potential breakthrough therapy?Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD
- Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibitionUnderstanding CKD and SGLT2-inhibition: What are the key mechanisms?
Prof. Per-Henrik Groop
- Epigenetics in CKD & CVD: A potential breakthrough therapy?Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics
Prof. Erik Stroes, MD
- Epigenetics in CKD & CVD: A potential breakthrough therapy?A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives
Kamyar Kalantar-Zadeh, MD
- InflammationAnti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease
Dr. Paul Ridker
